FDA under pressure from right after abortion pill approval

The anti-abortion movement’s patience with the Food and Drug Administration (FDA) is wearing thin following the agency’s recent approval of a second generic version of mifepristone, one of two drugs taken for a medication abortion.  

President Trump repeatedly pledged during the campaign last year that he would leave abortion policy to the states, but anti-abortion advocates and lawmakers have been pushing him to go further and sharply restrict the availability of mifepristone.